- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1450929-77-7] LHF-535
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-112762 |
| Brand: | MCE |
| CAS: | 1450929-77-7 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 412.52 |
| Molecular Formula | C27H28N2O2 |
| SMILES | OC(C)(C)C1=CC=C(/C=C\C2=CC=C3C(N=CN3C4=CC=C(OC(C)C)C=C4)=C2)C=C1 |
Summary
LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC 50 s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively [1] .
In Vitro
LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 exhibits potent antiviral activity against a broad array of hemorrhagic fever arenaviruses. LHF-535 inhibits Lassa GP-pseudotyped lentivirus with an IC 50 of 0.1-0.3 nM [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protectes mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver
[2]
.
An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection, demonstrating that LHF-535 is efficacious as a post-exposure therapeutic in mice
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | IFN-α/β and-γ receptor-deficient AG129 mice [2] |
| Dosage: | 3, 10, or 30 mg/kg/day |
| Administration: | Orally; daily; 14 days |
| Result: | Effective as a post-exposure therapeutic. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03993704 | Kineta Inc.|Wellcome Trust |
Healthy
|
September 16, 2019 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 96.67 mg/mL ( 234.34 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4241 mL | 12.1206 mL | 24.2412 mL |
| 5 mM | 0.4848 mL | 2.4241 mL | 4.8482 mL |
| 10 mM | 0.2424 mL | 1.2121 mL | 2.4241 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.42 mg/mL (5.87 mM); Clear solution
References
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.